Cargando…

Urinary kallidinogenase for the treatment of cerebral arterial stenosis

AIM: Urinary kallidinogenase (UK) has shown promise in improving cerebral perfusion. This study aimed to examine how UK affects cognitive status and serum levels of amyloid betas (Aβs) 1-40 and 1-42 in patients with cerebral arterial stenosis. METHODS: Ninety patients with cerebral arterial stenosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Liandong, Zhao, Ying, Wan, Qi, Zhang, Haijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4610775/
https://www.ncbi.nlm.nih.gov/pubmed/26508834
http://dx.doi.org/10.2147/DDDT.S93150
_version_ 1782395998305255424
author Zhao, Liandong
Zhao, Ying
Wan, Qi
Zhang, Haijun
author_facet Zhao, Liandong
Zhao, Ying
Wan, Qi
Zhang, Haijun
author_sort Zhao, Liandong
collection PubMed
description AIM: Urinary kallidinogenase (UK) has shown promise in improving cerebral perfusion. This study aimed to examine how UK affects cognitive status and serum levels of amyloid betas (Aβs) 1-40 and 1-42 in patients with cerebral arterial stenosis. METHODS: Ninety patients with cerebral arterial stenosis were enrolled, of whom 45 patients received UK + conventional treatment (UK group), and 45 patients received conventional treatment alone as control group. Cognitive status and Aβ1-40 and Aβ1-42 serum levels were determined before treatment and at 4 weeks and 8 weeks after treatment. RESULTS: At 4 weeks after treatment, cognitive status in patients treated with UK clearly improved accompanied by Aβ1-40 serum levels decreasing while there was no change of Aβ1-42. Cognitive status in patients receiving UK continued to improve, Aβ1-40 serum levels declined further as well as Aβ1-42 serum levels began to decrease dramatically at 8 weeks after treatment. CONCLUSION: UK could improve cognitive status and decrease both Aβ1-40 and Aβ1-42 serum levels to prevent ischemic cerebral injury, which represents a good option for patients with cerebral arterial stenosis.
format Online
Article
Text
id pubmed-4610775
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-46107752015-10-27 Urinary kallidinogenase for the treatment of cerebral arterial stenosis Zhao, Liandong Zhao, Ying Wan, Qi Zhang, Haijun Drug Des Devel Ther Original Research AIM: Urinary kallidinogenase (UK) has shown promise in improving cerebral perfusion. This study aimed to examine how UK affects cognitive status and serum levels of amyloid betas (Aβs) 1-40 and 1-42 in patients with cerebral arterial stenosis. METHODS: Ninety patients with cerebral arterial stenosis were enrolled, of whom 45 patients received UK + conventional treatment (UK group), and 45 patients received conventional treatment alone as control group. Cognitive status and Aβ1-40 and Aβ1-42 serum levels were determined before treatment and at 4 weeks and 8 weeks after treatment. RESULTS: At 4 weeks after treatment, cognitive status in patients treated with UK clearly improved accompanied by Aβ1-40 serum levels decreasing while there was no change of Aβ1-42. Cognitive status in patients receiving UK continued to improve, Aβ1-40 serum levels declined further as well as Aβ1-42 serum levels began to decrease dramatically at 8 weeks after treatment. CONCLUSION: UK could improve cognitive status and decrease both Aβ1-40 and Aβ1-42 serum levels to prevent ischemic cerebral injury, which represents a good option for patients with cerebral arterial stenosis. Dove Medical Press 2015-10-13 /pmc/articles/PMC4610775/ /pubmed/26508834 http://dx.doi.org/10.2147/DDDT.S93150 Text en © 2015 Zhao et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Zhao, Liandong
Zhao, Ying
Wan, Qi
Zhang, Haijun
Urinary kallidinogenase for the treatment of cerebral arterial stenosis
title Urinary kallidinogenase for the treatment of cerebral arterial stenosis
title_full Urinary kallidinogenase for the treatment of cerebral arterial stenosis
title_fullStr Urinary kallidinogenase for the treatment of cerebral arterial stenosis
title_full_unstemmed Urinary kallidinogenase for the treatment of cerebral arterial stenosis
title_short Urinary kallidinogenase for the treatment of cerebral arterial stenosis
title_sort urinary kallidinogenase for the treatment of cerebral arterial stenosis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4610775/
https://www.ncbi.nlm.nih.gov/pubmed/26508834
http://dx.doi.org/10.2147/DDDT.S93150
work_keys_str_mv AT zhaoliandong urinarykallidinogenaseforthetreatmentofcerebralarterialstenosis
AT zhaoying urinarykallidinogenaseforthetreatmentofcerebralarterialstenosis
AT wanqi urinarykallidinogenaseforthetreatmentofcerebralarterialstenosis
AT zhanghaijun urinarykallidinogenaseforthetreatmentofcerebralarterialstenosis